Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases.

IF 3.2 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-08-24 DOI:10.5306/wjco.v16.i8.107009

Xue-Jie Liu, Heng Ge, Chun-Luan Yuan

{"title":"Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases.","authors":"Xue-Jie Liu, Heng Ge, Chun-Luan Yuan","doi":"10.5306/wjco.v16.i8.107009","DOIUrl":null,"url":null,"abstract":"Background: The optimal sequencing of immune checkpoint inhibitor (ICI) and brain radiotherapy in the management of brain metastasis from non-small cell lung cancer (NSCLC) is unclear.Aim: To evaluate the survival of concurrent ICI and consolidation ICI in NSCLC patients treated with brain radiotherapy.Methods: We retrospectively analyzed NSCLC patients treated with brain radiotherapy and ICI. Treatment response and survival were estimated. The cox proportional hazards regression model was utilized to investigate the association between overall survival and clinical variables.Results: There were 54 patients in concurrent ICI and radiotherapy group, and 62 individuals treated with radiotherapy followed by consolidation ICI. The objective response rates were similar between the two group. The median progression free survival was significantly high in the concurrent ICI group compared with consolidation ICI group (9.56 months vs 8.15 months, P = 0.038). In addition, the median overall survival was 22.08 months in the concurrent ICI group, clearly longer than that in the consolidation group (13.24 months, P = 0.009).Conclusion: In NSCLC patients with brain metastases, our analyses suggested that radiotherapy concurrent with ICI was associated with significant benefit compared with radiotherapy followed by consolidation ICI.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107009"},"PeriodicalIF":3.2000,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400203/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i8.107009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The optimal sequencing of immune checkpoint inhibitor (ICI) and brain radiotherapy in the management of brain metastasis from non-small cell lung cancer (NSCLC) is unclear.

Aim: To evaluate the survival of concurrent ICI and consolidation ICI in NSCLC patients treated with brain radiotherapy.

Methods: We retrospectively analyzed NSCLC patients treated with brain radiotherapy and ICI. Treatment response and survival were estimated. The cox proportional hazards regression model was utilized to investigate the association between overall survival and clinical variables.

Results: There were 54 patients in concurrent ICI and radiotherapy group, and 62 individuals treated with radiotherapy followed by consolidation ICI. The objective response rates were similar between the two group. The median progression free survival was significantly high in the concurrent ICI group compared with consolidation ICI group (9.56 months vs 8.15 months, P = 0.038). In addition, the median overall survival was 22.08 months in the concurrent ICI group, clearly longer than that in the consolidation group (13.24 months, P = 0.009).

Conclusion: In NSCLC patients with brain metastases, our analyses suggested that radiotherapy concurrent with ICI was associated with significant benefit compared with radiotherapy followed by consolidation ICI.

Abstract Image

查看原文本刊更多论文

免疫检查点抑制剂联合放疗治疗脑转移非小细胞肺癌的生存益处

背景：免疫检查点抑制剂（ICI）和脑放疗在非小细胞肺癌（NSCLC）脑转移治疗中的最佳序列尚不清楚。目的：评价脑放疗治疗的非小细胞肺癌患者并发和巩固性ICI的生存率。方法：回顾性分析非小细胞肺癌患者接受脑放疗和ICI治疗的情况。评估治疗反应和生存期。采用cox比例风险回归模型研究总生存率与临床变量之间的关系。结果：同期ICI +放疗组54例，放疗+巩固性ICI组62例。两组的客观有效率相似。同期ICI组的中位无进展生存期明显高于合并ICI组（9.56个月vs 8.15个月，P = 0.038）。合并ICI组的中位总生存期为22.08个月，明显长于巩固组（13.24个月，P = 0.009）。结论：在脑转移的非小细胞肺癌患者中，我们的分析表明，与放疗后合并ICI相比，放疗合并ICI具有显著的获益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.